These findings indicate that CVM-A inhibits the critical components of the PI3K/Akt/mTOR pathway under tumor microenvironment mimicking condition of nutrition deprivation, reinforcing its potential as a candidate for pancreatic cancer drug development. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.